DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ketanserin is an investigational drug.
There have been 7 clinical trials for Ketanserin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Diabetic Foot, Shock, Septic, and Sepsis. The leading clinical trial sponsors are Gitte Moos Knudsen, Cell Pharma, SA de CV, and Psychiatric University Hospital, Zurich.
There is one US patent protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for Ketanserin
|Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)||Matthias Liechti||Early Phase 1|
|The Neurobiological Effect of 5-HT2AR Modulation||Gitte Moos Knudsen||Phase 1|
|The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers||Psychiatric University Hospital, Zurich||N/A|
Top disease conditions for Ketanserin
Top clinical trial sponsors for Ketanserin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ketanserin||Start Trial||Determining a modal amplitude of an inhomogeneous field with a quantum sensor||THE UNITED STATES OF AMERCA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (Washington, DC)||Start Trial|
|Ketanserin||Start Trial||Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder||Axovant Sciences GmbH (Basel, CH)||Start Trial|
|Ketanserin||Start Trial||Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent||Johnson & Johnson Consumer Inc. (Skillman, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|